Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
June 27, 2016
AxoGen (AXGN) Added to Russell 2000® Index
June 27, 2016
Cytori Therapeutics (CYTX) limited Japanese approval to treat Osteoarthritis
June 24, 2016
RegMed investors’ mid-day analysis: after Brexit, repricing of risk with heightened uncertainty
June 22, 2016
Pluristem (PSTI) just another pre-clinical mouse model
June 20, 2016
Fate Therapeutics (FATE) FDA Fast Track Designation
June 20, 2016
Sangamo BioSciences, Inc. (SGMO) another gene therapy IND
June 20, 2016
Kite Pharma, Inc. (KITE) and National Cancer Institute (NCI) initiate HPV research and clinical development projects
June 16, 2016
BioTime (NYSEMKT: BTX) prices 7.322 M share offering - $2.39
June 14, 2016
Mesoblast Limited (MESO) damage accessed, the aftermath …
June 14, 2016
Mesoblast (MESO) news is out, the prelim …
June 13, 2016
Northwest Bio (NWBO) a blood trail to follow, find yourself a home or seek protection
June 13, 2016
Neuralstem (CUR) the next TOEs up
June 13, 2016
Gene therapy: 3 patients, 4 patients, 5 patients, 6 …
June 13, 2016
Fibrocell (FCSC) another P1/2 starts after one fails
June 13, 2016
Spark Therapeutics (ONCE) four subject trial results - BUY
June 13, 2016
uniQure (QURE) P1/2 data show relevant Factor IX (FIX) expression - BUY
June 10, 2016
Mesoblast (MESO) NO end to trading HALT
June 8, 2016
Fibrocell Science (FCSC) P2 misses endpoint, -47.72% share pricing drop
June 7, 2016
Mesoblast (MESO) expects shares to remain halted until June 10th
June 7, 2016
ImmunoCellular Therapeutics (NYSEMKT: IMUC) Treats first patient
June 7, 2016
Applied Genetic Technologies (AGTC) Orphan Medicinal Product Designation in EU
June 3, 2016
Kite Pharma (KITE) adds $6 M Investment in Cell Design Labs
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.